{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T04:38:12Z","timestamp":1725683892252},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,3]],"date-time":"2014-01-03T00:00:00Z","timestamp":1388707200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s40258-013-0071-8","type":"journal-article","created":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T12:18:58Z","timestamp":1388665138000},"page":"103-115","source":"Crossref","is-referenced-by-count":7,"title":["Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia"],"prefix":"10.1007","volume":"12","author":[{"given":"Ursula","family":"Rochau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby","family":"Sroczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kluibenschaedl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Brixner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,3]]},"reference":[{"key":"71_CR1","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/cncr.22661","volume":"109","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Cortes JE, Giles FJ, O\u2019Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109:2171\u201381.","journal-title":"Cancer"},{"key":"71_CR2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370:342\u201350.","journal-title":"Lancet"},{"key":"71_CR3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"71_CR4","doi-asserted-by":"crossref","unstructured":"Mealing S, Barcena L, Hawkins N, et al. Chronic myeloid leukemia: therapy. Poster III: comparative efficacy of first line treatment of chronic myeloid leukaemia (CML): a systematic review and meta-analysis. 2010: Blood (ASH Annual Meeting Abstracts); 2010.","DOI":"10.1182\/blood.V116.21.3436.3436"},{"key":"71_CR5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10198-003-0205-2","volume":"4","author":"U Siebert","year":"2003","unstructured":"Siebert U. When should decision-analytic modeling be used in the economic evaluation of health care? Eur J Health Econ. 2003;4:143\u201350.","journal-title":"Eur J Health Econ"},{"key":"71_CR6","volume-title":"Introductory lectures on choices under uncertainty","author":"H Raiffa","year":"1968","unstructured":"Raiffa H. Introductory lectures on choices under uncertainty. New York: Random House; 1968."},{"key":"71_CR7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJM197703312961304","volume":"296","author":"MC Weinstein","year":"1977","unstructured":"Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716\u201321.","journal-title":"N Engl J Med"},{"key":"71_CR8","volume-title":"Clinical decision analysis","author":"M Weinstein","year":"1980","unstructured":"Weinstein M, Fineberg H, Elstein A, Frazier H, Neuhauser D, Neutra R, McNeil B. Clinical decision analysis. Philadelphia: W.B. Saunders Company; 1980."},{"key":"71_CR9","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"1997","unstructured":"Drummond M, O\u2019Brien S, Stoddard G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd ed. New York: Oxford University Press; 1997.","edition":"2"},{"key":"71_CR10","volume-title":"Decision making in health and medicine:integrating evidence and values","author":"MG Hunink","year":"2001","unstructured":"Hunink MG, Glasziou P, Siegel J, Weeks J, Pliskin J, Elstein A, Weinstein M. Decision making in health and medicine:integrating evidence and values. Cambridge: Cambridge University Press; 2001."},{"key":"71_CR11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1524-4733.2003.00234.x","volume":"6","author":"MC Weinstein","year":"2003","unstructured":"Weinstein MC, O\u2019Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, Luce BR. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices\u2014Modeling Studies. Value Health. 2003;6:9\u201317.","journal-title":"Value Health"},{"key":"71_CR12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1524-4733.2004.75012.x","volume":"7","author":"U Siebert","year":"2004","unstructured":"Siebert U, Bornschein B, Walbert T, Dodel RC. Systematic assessment of decision models in Parkinson\u2019s disease. Value Health. 2004;7:610\u201326.","journal-title":"Value Health"},{"key":"71_CR13","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost-effectiveness in health and medicine","author":"M Gold","year":"1996","unstructured":"Gold M, Siegel J, Russell J, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996."},{"key":"71_CR14","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","volume":"276","author":"MC Weinstein","year":"1996","unstructured":"Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1253\u20138.","journal-title":"JAMA"},{"key":"71_CR15","unstructured":"ISPOR. Joint Modeling Good Research Practices Task Force [Internet]. \u00a92012 International Society for Pharmacoeconomics and Outcomes Research. http:\/\/www.ispor.org\/TaskForces\/GRPModelingTf.asp . Accessed 14 Oct 2011."},{"key":"71_CR16","volume-title":"Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care","author":"Centre for Reviews and Dissemination","year":"2009","unstructured":"Centre for Reviews and Dissemination. Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care. York: University of York, CRD; 2009."},{"key":"71_CR17","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1200\/JCO.1997.15.7.2673","volume":"15","author":"NL Liberato","year":"1997","unstructured":"Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol. 1997;15:2673\u201382.","journal-title":"J Clin Oncol"},{"key":"71_CR18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s007610050409","volume":"5","author":"N Liberato","year":"1999","unstructured":"Liberato N, Barosi G. Kosteneffektivit\u00e4t der Interferontherapie bei chronisch myeloischer Leuk\u00e4mie. Onkologe. 1999;5:586\u20139.","journal-title":"Onkologe"},{"key":"71_CR19","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.3310\/hta8280","volume":"8","author":"K Dalziel","year":"2004","unstructured":"Dalziel K, Round A, Stein K, Garside R, Price A. Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess. 2004;8:iii1\u2013120.","journal-title":"Health Technol Assess"},{"key":"71_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16220","volume":"16","author":"G Rogers","year":"2012","unstructured":"Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess. 2012;16:1\u2013410.","journal-title":"Health Technol Assess"},{"key":"71_CR21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00019053-200523050-00010","volume":"23","author":"K Dalziel","year":"2005","unstructured":"Dalziel K, Round A, Garside R, Stein K. Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics. 2005;23:515\u201326.","journal-title":"Pharmacoeconomics"},{"key":"71_CR22","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","volume":"14","author":"M Hoyle","year":"2011","unstructured":"Hoyle M, Rogers G, Moxham T, Liu Z, Stein K. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011;14:1057\u201367.","journal-title":"Value Health"},{"key":"71_CR23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3111\/13696990802354683","volume":"11","author":"L Breitscheidel","year":"2008","unstructured":"Breitscheidel L. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. J Med Econ. 2008;11:571\u201384.","journal-title":"J Med Econ"},{"key":"71_CR24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.7326\/0003-4819-127-12-199712150-00005","volume":"127","author":"SJ Lee","year":"1997","unstructured":"Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med. 1997;127:1080\u20138.","journal-title":"Ann Intern Med"},{"key":"71_CR25","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood.V92.11.4047","volume":"92","author":"SJ Lee","year":"1998","unstructured":"Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998;92:4047\u201352.","journal-title":"Blood"},{"key":"71_CR26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1592\/phco.25.3.325.61593","volume":"25","author":"GH Skrepnek","year":"2005","unstructured":"Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005;25:325\u201334.","journal-title":"Pharmacotherapy"},{"key":"71_CR27","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta16230","volume":"16","author":"E Loveman","year":"2012","unstructured":"Loveman E, Cooper K, Bryant J, Colquitt JL, Frampton GK, Clegg A. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess. 2012;16:iii\u2013xiii 1\u2013137.","journal-title":"Health Technol Assess"},{"key":"71_CR28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-125-7-199610010-00002","volume":"125","author":"MW Kattan","year":"1996","unstructured":"Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med. 1996;125:541\u20138.","journal-title":"Ann Intern Med"},{"key":"71_CR29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/10428190109057960","volume":"41","author":"JR Beck","year":"2001","unstructured":"Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia. Leuk Lymphoma. 2001;41:117\u201324.","journal-title":"Leuk Lymphoma"},{"key":"71_CR30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/A:1008212411489","volume":"9","author":"A Messori","year":"1998","unstructured":"Messori A. Cost-effectiveness of interferon in chronic myeloid leukaemia: analysis of four clinical studies. Ann Oncol. 1998;9:389\u201396.","journal-title":"Ann Oncol"},{"key":"71_CR31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/sj.bjc.6601151","volume":"89","author":"A Gordois","year":"2003","unstructured":"Gordois A, Scuffham P, Warren E, Ward S. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer. 2003;89:634\u201340.","journal-title":"Br J Cancer"},{"key":"71_CR32","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.clinthera.2004.11.007","volume":"26","author":"E Warren","year":"2004","unstructured":"Warren E, Ward S, Gordois A, Scuffham P. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase. Clin Ther. 2004;26:1924\u201333.","journal-title":"Clin Ther"},{"issue":"Suppl 3","key":"71_CR33","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1111\/j.1524-4733.2009.00635.x","volume":"12","author":"Z Chen","year":"2009","unstructured":"Chen Z, Wang C, Xu X, Feng W. Cost-effectiveness study comparing imatinib with interferon-alpha for patients with newly diagnosed chronic-phase (CP) chronic myeloid leukemia (CML) from the Chinese public health-care system perspective (CPHSP). Value Health. 2009;12(Suppl 3):S85\u20138.","journal-title":"Value Health"},{"key":"71_CR34","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1002\/cncr.20694","volume":"101","author":"SD Reed","year":"2004","unstructured":"Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101:2574\u201383.","journal-title":"Cancer"},{"key":"71_CR35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00019053-200826050-00007","volume":"26","author":"SD Reed","year":"2008","unstructured":"Reed SD, Anstrom KJ, Li Y, Schulman KA. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics. 2008;26:435\u201346.","journal-title":"Pharmacoeconomics"},{"key":"71_CR36","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta16420","volume":"16","author":"T Pavey","year":"2012","unstructured":"Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol Assess. 2012;16:iii\u2013iv 1\u2013277.","journal-title":"Health Technol Assess"},{"key":"71_CR37","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/0284186X.2010.495132","volume":"49","author":"O Ghatnekar","year":"2010","unstructured":"Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib: a Swedish model application. Acta Oncol. 2010;49:851\u20138.","journal-title":"Acta Oncol"},{"key":"71_CR38","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","volume":"32","author":"U Siebert","year":"2012","unstructured":"Siebert U, Alagoz O, Bayoumi A, Jahn B, Owens D, Cohen D, Kuntz K. ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Mak. 2012;32:690\u2013700.","journal-title":"Med Decis Mak"},{"key":"71_CR39","unstructured":"Comprehensive Cancer Network (NCCN). NCCN clinical practical guidelines in oncology (NCCN Guidelines) chronic myelogenous leukemia. Version 2.2014; 2013. p. 1\u201391."},{"key":"71_CR40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"A Briggs","year":"2012","unstructured":"Briggs A, Weinstein M, Fenwick E, Karnon J, Sculpher M, Paltiel A. ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Mak. 2012;32:722\u201332.","journal-title":"Med Decis Mak"},{"key":"71_CR41","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/oso\/9780195108248.003.0008","volume-title":"Cost-effectiveness in health and medicine","author":"WG Manning","year":"1996","unstructured":"Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p. 247\u201375."},{"key":"71_CR42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0272989X0002000308","volume":"20","author":"EF Halpern","year":"2000","unstructured":"Halpern EF, Weinstein MC, Hunink MG, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Mak. 2000;20:314\u201322.","journal-title":"Med Decis Mak"},{"key":"71_CR43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479\u2013500.","journal-title":"Pharmacoeconomics"},{"key":"71_CR44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00019053-200624110-00003","volume":"24","author":"KP Claxton","year":"2006","unstructured":"Claxton KP, Sculpher MJ. Using value of information analysis to prioritise health research: some lessons from recent UK experience. Pharmacoeconomics. 2006;24:1055\u201368.","journal-title":"Pharmacoeconomics"},{"key":"71_CR45","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Health and Clinical Excellence","year":"2008","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Care Excellence (NICE); 2008."},{"key":"71_CR46","volume-title":"Process and methods guides: guide to the methods of technology appraisal 2013","author":"National Institute for Health and Clinical Excellence","year":"2013","unstructured":"National Institute for Health and Clinical Excellence. Process and methods guides: guide to the methods of technology appraisal 2013. London: National Institute for Health and Care Excellence (NICE); 2013."},{"key":"71_CR47","unstructured":"Statens beredning f\u00f6r medicinsk utv\u00e4rdering. Utv\u00e4rdering av metoder i h\u00e4lso- och sjukv\u00e5rden. En handbok. Version 2012:1:1. Stockholm, Sweden; 2012. p. 1\u2013245"},{"key":"71_CR48","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"D Eddy","year":"2012","unstructured":"Eddy D, Hollingworth W, Caro J, Tsevat J, McDonald K, Wong J. ISPOR-SMDM Modeling Good Research Practices Task Force. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Mak. 2012;32:733\u201343.","journal-title":"Med Decis Mak"},{"key":"71_CR49","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/0272989X12454941","volume":"32","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell L, Paltiel A, Chambers M, McEwan P, Krahn M. ISPOR-SMDM Modeling Good Research Practices Task Force. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Med Decis Mak. 2012;32:678\u201389.","journal-title":"Med Decis Mak"},{"key":"71_CR50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.02.005","volume":"96","author":"JJ Carlson","year":"2010","unstructured":"Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy. 2010;96:179\u201390.","journal-title":"Health Policy"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0071-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-013-0071-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-013-0071-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T12:27:39Z","timestamp":1716380859000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-013-0071-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,3]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s40258-013-0071-8","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,3]]}}}